The risk assessment tool could help health systems and researchers alike determine when patients face greater odds of post-PCI complications. 

It is an announcement many interventional cardiologists have been waiting to hear for a long time. 

Researchers have completed a new analysis of the Evolut Pro and Pro+ devices from Medtronic and the Sapien 3 Ultra devices from Edwards Lifesciences, sharing the results in JACC: Cardiovascular Interventions.

The Impella RP System is still associated with significant benefits, the FDA said, but there are certain high-risk patients who should no longer be eligible for treatment.

A randomized study of more than 450 patients with persistent atrial fibrillation is now underway. All patients have been treated, and their outcomes will be tracked for 12 months. 

Getinge has provided a detailed breakdown of the shortage, stating that it is not yet clear when it may be over. The FDA said it will keep a close eye on the situation and provide updates when possible. 

Nontraditional risk factors such as dementia, PTSD, bipolar disorder and low socioeconomic status are all important to consider when patients are candidates for aortic valve replacement. 

The new study, published in Circulation, represents a collaboration between specialists from a variety of facilities, including Cleveland Clinic and the University of Arizona.